Clinical Trial Update: Study of Ad-RTS-hIL-12 + Veledimex in Combination With Cemiplimab in Subjects With Recurrent or Progressive Glioblastoma [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating Ad-RTS-hIL-12 plus Veledimex in combination with cemiplimab for recurrent or progressive glioblastoma was terminated; results have been…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glioblastoma

Drugs mentioned

• Ad-RTS-hIL-12 (Adenoviral vector encoding human interleukin-12 under Rheostatic Transcriptional System)
• Cemiplimab (Libtayo) (cemiplimab)
• Veledimex (Veledimex; small-molecule activator of the RheoSwitch Therapeutic System)

Snippet

Sponsor: Alaunos Therapeutics | Conditions: Glioblastoma | Phase 2 | Status: TERMINATED | Results posted: 2025-04-18